Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV.

Journal Article (Journal Article)

BACKGROUND: Substantial body composition alterations have been reported after starting combined antiretroviral therapy (cART). We characterized a cohort of chronically infected and virologically suppressed (VL < 50 copies/ml) men (≥50 years old) living with HIV (MLWH) who were switched to integrase inhibitors (INSTI), and compared their body composition parameters and proinflammatory/endocrine profiles to age-matched MLWH on integrase inhibitor free (non-INSTI) regimens, taking into account neighborhood-level measures of socioeconomic status (SES). In addition, we used previously published HIV-seronegative men of the same age as controls. METHODS: We used dual energy X-ray absorptiometry to quantify body composition parameters, and measured plasma proinflammatory/endocrine markers in 56 MLWH. We compared body composition to a publicly available dataset of 450 HIV-seronegative men of similar age. Within the MLWH group, body composition and plasma proinflammatory/endocrine markers were compared between individuals on INSTI and non-INSTI regimens, accounting for SES. RESULTS: Men living with HIV tended to have a greater android/gynoid ratio compared to HIV-seronegative men (p < 0.001). INSTI usage in MLWH was associated with lower adiposity measures when compared to non-INSTI, although these differences largely disappeared after controlling for SES. Proinflammatory/endocrine markers were similar for INSTI and non-INSTI MLWH. CONCLUSIONS: Among cART-experienced MLWH, those receiving INSTI-containing regimens had modestly lower adiposity compared to non-INSTI MLWH, although these differences were explained by SES. Future studies examining the relationship between INSTI use and body composition should consider the impact of SES.

Full Text

Duke Authors

Cited Authors

  • Wisch, JK; Cooley, SA; Yarasheski, KE; Cade, WT; Reeds, DN; Nelson, B; Alemu, R; Burdo, TH; Ances, BM

Published Date

  • June 2022

Published In

Volume / Issue

  • 27 / 3

Start / End Page

  • 13596535221109748 -

PubMed ID

  • 35730471

Electronic International Standard Serial Number (EISSN)

  • 2040-2058

Digital Object Identifier (DOI)

  • 10.1177/13596535221109748


  • eng

Conference Location

  • England